Breaking through the barriers that
prevent rapid, comprehensive
Every patient deserves the best treatment options
More than 200 targeted therapies are now approved for the treatment of cancer, offering patients better outcomes and renewed hope. However, fewer than 50% of patients have access to the comprehensive biomarker testing needed to access these lifesaving treatments.1
The primary barrier limiting access is the time it takes for current solutions to deliver test results. Typically, weeks from diagnosis. Patients with advanced cancers do not have the luxury of waiting weeks to start therapy, leaving physicians with the difficult choice of starting their patients on systemic, toxic chemotherapies.
Sequencing technologies are ideally suited for research purposes but were not designed for routine use in local clinical settings, where delays in starting therapy could negatively impact patient outcomes.
ASPYRE® is a new biomarker testing technology that was specifically developed to provide comprehensive biomarker results within days of diagnosis, giving physicians the opportunity to offer their patients the best possible treatment options.
1Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers, Anita Chawla, et. al., Journal of Medical Economics, 2018, Vol. 21, No. 6, 543-552
ASPYRE's unique advantages
Simple and adaptable
ASPYRE can be rapidly implemented on existing PCR instrumentation without the need for highly trained laboratory staff, sample batching, or complex bioinformatics, requiring only transfer and addition of reagents.
Fast time to treatment
ASPYRE is a patented molecular chemistry that uses a unique enzymatic reaction to dramatically accelerate the detection of actionable biomarkers from blood or tissue within hours vs. weeks for sequencing technologies.
With the ability to detect as little as one molecule of mutated DNA or RNA1, ASPYRE is up to 10 times more sensitive than NGS and 50 times more sensitive than single-gene PCR tests.
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, providing accuracy for the markers that are of interest and enabling more confident decision-making.
Reduced sample requirements
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, as compared to 20% to 30% for most alternative assays, minimizing the frustration associated with QNS and QC failure rates.
At a fraction of the cost of NGS, ASPYRE was invented to increase patient access to biomarker testing and is suitable for repeat testing and patient monitoring.
1Single-copy detection of somatic variants from solid and liquid biopsy, Scientific Reports, Mar 16: 10.1038/s4 1598-021-85545-3
Featured resources & publications
ASPYRE-Lung now available
By simplifying the detection of genomic biomarkers, use of ASPYRE-Lung as a first-line diagnostic helps identify those NSCLC patients who will likely benefit from precision medicine in a fraction of the time and at a fraction of the cost of NGS.